Research ExplorerPublicationsAktuelle Therapiekonzepte bei kastrationsresistenten Prostat...

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom

Standard

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom. / Amsberg, Gunhild; Strölin, Petra; Bokemeyer, C; Steuber, Thomas.

In: DEUT MED WOCHENSCHR, Vol. 139, No. 41, 01.10.2014, p. 2086-90.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Amsberg, G, Strölin, P, Bokemeyer, C & Steuber, T 2014, 'Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom', DEUT MED WOCHENSCHR, vol. 139, no. 41, pp. 2086-90. https://doi.org/10.1055/s-0034-1387276

APA

Amsberg, G., Strölin, P., Bokemeyer, C., & Steuber, T. (2014). Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom. DEUT MED WOCHENSCHR, 139(41), 2086-90. https://doi.org/10.1055/s-0034-1387276

Vancouver

Amsberg G, Strölin P, Bokemeyer C, Steuber T. Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom. DEUT MED WOCHENSCHR. 2014 Oct 1;139(41):2086-90. https://doi.org/10.1055/s-0034-1387276

Bibtex

@article{6760a43f2add4c0f9d18c19c31ebc531,
title = "Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom",
abstract = "Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date. Alpha emitter Radium-223 has the ability to mimic calcium and target bone metastases. Thus, it is a reasonable therapeutic alternative for patients suffering from symptomatic bone metastases. In 2013, Sipuleucel-T was the first immunotherapy approved for CRPC in Europe. In this review we introduce the different therapeutic options to the reader, reflect the possible therapeutic sequences and give a perspective on novel pipeline medications.",
keywords = "Antibodies, Monoclonal, Antineoplastic Agents, Brachytherapy, Combined Modality Therapy, Evidence-Based Medicine, Humans, Male, Molecular Targeted Therapy, Prostatic Neoplasms, Castration-Resistant, Taxoids",
author = "Gunhild Amsberg and Petra Str{\"o}lin and C Bokemeyer and Thomas Steuber",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2014",
month = oct,
day = "1",
doi = "10.1055/s-0034-1387276",
language = "Deutsch",
volume = "139",
pages = "2086--90",
journal = "DEUT MED WOCHENSCHR",
issn = "0012-0472",
publisher = "Georg Thieme Verlag KG",
number = "41",

}

RIS

TY - JOUR

T1 - Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom

AU - Amsberg, Gunhild

AU - Strölin, Petra

AU - Bokemeyer, C

AU - Steuber, Thomas

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date. Alpha emitter Radium-223 has the ability to mimic calcium and target bone metastases. Thus, it is a reasonable therapeutic alternative for patients suffering from symptomatic bone metastases. In 2013, Sipuleucel-T was the first immunotherapy approved for CRPC in Europe. In this review we introduce the different therapeutic options to the reader, reflect the possible therapeutic sequences and give a perspective on novel pipeline medications.

AB - Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date. Alpha emitter Radium-223 has the ability to mimic calcium and target bone metastases. Thus, it is a reasonable therapeutic alternative for patients suffering from symptomatic bone metastases. In 2013, Sipuleucel-T was the first immunotherapy approved for CRPC in Europe. In this review we introduce the different therapeutic options to the reader, reflect the possible therapeutic sequences and give a perspective on novel pipeline medications.

KW - Antibodies, Monoclonal

KW - Antineoplastic Agents

KW - Brachytherapy

KW - Combined Modality Therapy

KW - Evidence-Based Medicine

KW - Humans

KW - Male

KW - Molecular Targeted Therapy

KW - Prostatic Neoplasms, Castration-Resistant

KW - Taxoids

U2 - 10.1055/s-0034-1387276

DO - 10.1055/s-0034-1387276

M3 - SCORING: Zeitschriftenaufsatz

C2 - 25268211

VL - 139

SP - 2086

EP - 2090

JO - DEUT MED WOCHENSCHR

JF - DEUT MED WOCHENSCHR

SN - 0012-0472

IS - 41

ER -